Fecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and results

E Reigadas, M Olmedo, M Valerio, S Vázquez-Cuesta, L Alcalá, M Marín, P Muñoz, E Bouza, E Reigadas, M Olmedo, M Valerio, S Vázquez-Cuesta, L Alcalá, M Marín, P Muñoz, E Bouza

Abstract

Objective: Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent Clostridium difficile infection (R-CDI). Despite its excellent efficacy, it is still not a routine procedure in most European centers. FMT has not been widely used in Spain to date. We describe our experience with FMT, including a novel approach based on oral fecal capsules.

Methods: We analyzed a prospectively recorded case series of patients with R-CDI treated with FMT at a single center (June 2014-July 2017). Primary outcome was defined as resolution of CDI without recurrence in a two-month period. FMT was administered via colonoscopy, nasojejunal tube, or oral capsules. All stool donors were rigorously screened.

Results: FMT was performed in 13 patients with R-CDI. Median age was 75.0 years and 76.9% were females. Six FMT were performed via nasojejunal tube, 5 via oral capsules, and 2 by colonoscopy. There were no procedure-related adverse events, except for bacteremia in one patient. During follow-up, R- CDI was observed in one patient at one month after FMT. The primary resolution rate was 83.3% and the overall resolution rate was 91.7%. FMT by capsules achieved a 100% resolution rate, colonoscopy 100%, and nasojejunal tube 80.0%.

Conclusions: In our cohort, FMT proved to be safe and effective, even in high risk patients. Oral administration in capsules also proved to be safe, well-tolerated, and highly effective for R-CDI. In our experience, the FMT capsule formulation seems feasible in the routine of a hospital. This administration method will allow FMT to be more widely used.

Conflict of interest statement

The authors declare no conflicts of interest.

©The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).

Figures

Figure 2
Figure 2
Microbiome analysis for patient #12 and its donor
Figure 1
Figure 1
Oral capsules for fecal transplant

References

    1. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012; 55 Suppl 2: S88-92. doi:10.1093/cid/cis335.
    1. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in europe: A systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012; 81: 1-14. doi:10.1016/j.jhin.2012.02.004.
    1. Asensio A, Bouza E, Grau S, Rubio-Rodriguez D, Rubio-Terres C. [cost of clostridium difficile associated diarrhea in spain]. Rev Esp Salud Publica. 2013; 87: 25-33. doi:10.4321/s1135-57272013000100004.
    1. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial clostridium difficile-associated diarrhea in canadian hospitals. Infect Control Hosp Epidemiol. 2002; 23: 137-140. doi:10.1086/502023.
    1. Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014; 20 Suppl 2: 1-26. doi:10.1111/1469-0691.12418.
    1. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. . Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017; 376: 305-317. doi:10.1056/NEJMoa1602615.
    1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. . Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of america (SHEA) and the infectious diseases society of america (IDSA). Infect Control Hosp Epidemiol. 2010; 31: 431-455. doi:10.1086/651706.
    1. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. . Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368: 407-415. doi:10.1056/NEJMoa1205037.
    1. Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. . Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: A randomized, open-label, controlled pilot study. Clin Infect Dis. 2014; 58: 1515-1522. doi:10.1093/cid/ciu135.
    1. Moayyedi P, Yuan Y, Baharith H, Ford AC. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: A systematic review of randomised controlled trials. Med J Aust. 2017; 207: 166-172.
    1. Staley C, Hamilton MJ, Vaughn BP, Graiziger CT, Newman KM, Kabage AJ, et al. . Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol. 2017; 112: 940-947. doi:10.1038/ajg.2017.6.
    1. Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. . Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: A randomized clinical trial. JAMA. 2017; 318: 1985-1993. doi:10.1001/jama.2017.17077.
    1. Lopez-Sanroman A, Rodriguez de Santiago E, Cobo Reinoso J, Del Campo Moreno R, Foruny Olcina JR, Garcia Fernandez S, et al. . Results of the implementation of a multidisciplinary programme of faecal microbiota transplantation by colonoscopy for the treatment of recurrent Clostridium difficile infection. Gastroenterol Hepatol. 2017; 40: 605-614. doi:10.1016/j.gastrohep.2017.03.004.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40: 373-383.
    1. McCabe WR, Jackson G.G. Gram-negative bacteremia I. Etiology and ecology. Arch Intern Med. 1962; 110: 847–855. doi:10.1001/archinte.1962.03620240029006.
    1. Chapman BC, Moore HB, Overbey DM, Morton AP, Harnke B, Gerich ME, et al. . Fecal microbiota transplant in patients with Clostridium difficile infection: A systematic review. J Trauma Acute Care Surg. 2016; 81: 756-764. doi:10.1097/ta.0000000000001195.
    1. Tang G, Yin W, Liu W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory clostridium difficile infection: A meta-analysis? Diagn Microbiol Infect Dis. 2017; 88: 322-329. doi:10.1016/j.diagmicrobio.2017.05.007.
    1. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014; 312: 1772- 1778. doi:10.1001/jama.2014.13875.
    1. Youngster I, Mahabamunuge J, Systrom HK, Sauk J, Khalili H, Levin J, et al. . Oral, frozen fecal microbiota transplant (fmt) capsules for recurrent Clostridium difficile infection. BMC Med. 2016; 14: 134. doi:10.1186/s12916-016-0680-9.
    1. Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (fmt) for Clostridium difficile infection: Focus on immunocompromised patients. J Infect Chemother. 2015; 21: 230-237. doi:10.1016/j.jiac.2015.01.011.
    1. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA et al. ,Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011; 9: 1044-1049. doi:10.1016/j.cgh.2011.08.014.
    1. Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant. 2014; 14: 477- 480. doi:10.1111/ajt.12577.
    1. van Beurden YH, Nieuwdorp M, van de Berg P, Mulder CJJ, Goorhuis A. Current challenges in the treatment of severe clostridium difficile infection: Early treatment potential of fecal microbiota transplantation. Therap Adv Gastroenterol. 2017; 10: 373-381. doi:10.1177/1756283x17690480.
    1. Lagier JC, Delord M, Million M, Parola P, Stein A, Brouqui P, et al. . Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: A preliminary report. Eur J Clin Microbiol Infect Dis. 2015; 34: 1597-1601. doi:10.1007/s10096-015-2394-x.
    1. Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, et al. . Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013; 51: 2884-2892. doi:10.1128/jcm.00845-13.
    1. Schubert AM, Rogers MA, Ring C, Mogle J, Petrosino JP, Young VB, et al. . Microbiome data distinguish patients with Clostridium difficile infection and non-c. Difficile-associated diarrhea from healthy controls. MBio. 2014; 5: e01021-01014. doi:10.1128/mBio.01021-14.
    1. Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, et al. . Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016; 43: 1142-1153. doi:10.1111/apt.13616.
    1. Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, et al. . Gut microbiome predictors of treatment response and recurrence in primary clostridium difficile infection. Aliment Pharmacol Ther. 2016; 44: 715-727. doi:10.1111/apt.13750.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner